Figure 3:

A) Real-time changes in ECAR (left), basal ECAR and maximal glycolytic capacity (MGC) quantifications (right) of BMDMs untreated or treated with LPS (1 μg ml⁻¹) and then challenged with different doses of oxPAPC, as indicated. B) Real-time changes in OCR (left), basal OCR and maximal respiratory capacity (MRC) quantifications (right) of BMDMs treated as in A. n = 6, graphs are representative of three independent experiments and show means ± SEM. Statistical significance was calculated using two-way ANOVA and Dunnett’s multiple comparisons test. C) BMDMs were primed, or not, with LPS and then stimulated with oxPAPC (100, 50 or 25 μg ml⁻¹). AKT phosphorylation was analyzed after 1h by immunoblotting. D) BMDMs were primed, or not, with LPS and then stimulated with oxPAPC (100 μg ml⁻¹). AKT phosphorylation was analyzed at the indicate time points by immunoblotting. E) BMDMs were primed, or not, with LPS and then treated with DPPC (100, 50 or 25 μM). AKT phosphorylation was analyzed after 1h by immunoblotting. Images are representative of three independent experiments. F) BMDMs were primed with LPS and then stimulated with oxPAPC (100, 50 or 25 μg ml⁻¹) (n = 4) (left) or AKTi (10, 5, 25 μM) (n = 9) (right). IL-10 and TNF production was quantified by ELISA 18h later. Graphs are representative of four independent experiments and show means ± SEM. Statistical multiple comparisons were calculated by two-way ANOVA and Dunnett’s test.